Asthma News – October 4, 2022
Current asthma research, announcements and opportunities, collected and distributed by Michigan Department of Health & Human Services (MDHHS) Asthma Program Staff.
Sign up to receive weekly-ish news emails.
Check out the most recent
MDHHS asthma social media messages and share them with your networks.
This webinar will help you: gain understanding of the changing landscape of tobacco and nicotine products when assessing patients; assess the latest evidence on ENDS safety, health impact and cessation efficacy; describe the unique aspects in assessing use behaviors and nicotine dependence for ENDS users, and; develop evidence-based strategies to assist with ENDS cessation.
This child-friendly, colorful guide explains what asthma is, what triggers it, and how an asthma management plan can help. It is available for free in Adobe Acrobat PDF format in both English and Spanish.
Researchers found no clinically important differences in the proportions of patients with ‘well-controlled’ or ‘partly controlled’ asthma symptoms, or proportions who improved or maintained their level of control, with as-needed budesonide–formoterol versus maintenance budesonide plus short-acting beta2-agonist (SABA).
Heart disease, asthma, and anxiety disorders were the chronic conditions most strongly associated with medical debt in lower-income households.
A large population-based study found that more frequent asthma exacerbations are associated with faster lung function decline. This was more prominent in younger patients but was evident in older patients when it was related to lower starting lung function, suggesting a persistent deteriorating phenotype that develops in adulthood over time.
A new systematic review and indirect treatment comparison of 16 randomized controlled trials supports the use of tezepelumab in a broad patient population of severe uncontrolled asthma of any phenotype.